Supreme Court appears open to Starbucks’ claims in labor-organizing case 
US Supreme Court Signals Support for Starbucks in Landmark Labor Law Case 
Tesla to Lay Off 2,700 in Austin, Over 3,300 in California Under Restructuring Scheme 
The language of insolvency: why getting it wrong can harm struggling firms 
7-Eleven Reveals Global Growth Plan to Boost Its F&B Programs 
Huawei Introduces Smart Driving Software Brand Qiankun 
LG Energy Solution to Combat Infringement By Launching Licensing Business for Battery Patents 
Why is the London Stock Exchange losing out to the US 
Crypto.com's Launch in South Korea Stalled by AML Regulatory Concerns, Postponement Announced 
Boeing Provides $425 Million Financial Support for Spirit AeroSystems Amid Production Challenges 
Hollys Brews Expansion with First Overseas Outlet in Japan in May 
Volvo Cars Projects Robust Demand Despite Financial Hiccups in Q1 
PepsiCo Surpasses $18 Billion Revenue Expectations Amid Strong International Demand 
SEC Postpones Grayscale's Ethereum ETF Decision Amid Tighter Crypto Scrutiny 
Tesla Wipes Out New Content Marketing Unit, Fired All Team Members 
Tesla Nears FSD Licensing Deal with Major Automaker, Hits 1.3 Billion Milestone 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
Pfizer Inc.'s application for emergency use authorization in the US for its potential coronavirus vaccine will be not earlier than the third week of November.
The US pharmaceutical giant is one of several companies during final-stage clinical trials for potential coronavirus vaccines in the country.
According to Chairman and CEO Albert Bourla, Pfizer may find out later this month whether or not its vaccine can help prevent COVID-19 in at least a majority of those vaccinated.
if data from trials support the move, Pfizer will apply for emergency use authorization in the US after the safety milestone is achieved in the third week of November.
The US Food and Drug Administration requires companies to provide two months of safety data on half of the trial participants following the final dose of the vaccine.
Pfizer, which is developing the vaccine with Germany's BioNTech SE, has agreed to supply Japan with 120 million doses of a vaccine for 60 million people if the development efforts are successful.
Another American pharmaceutical firm Moderna Inc. revealed it wouldn't be ready to seek emergency use authorization before Nov. 25.
US President Donald Trump has been raising expectations that vaccines could be ready before the Nov. 3 presidential election.
